98%
921
2 minutes
20
Exposure to particulate matter air pollution has been causally linked to cardiovascular disease in humans. Several broad and overlapping hypotheses describing the biological mechanisms by which particulate matter exposure leads to cardiovascular disease have been explored, although linkage with specific factors or genes remains limited. These hypotheses may or may not also lead to particulate matter-induced cardiac dysfunction. Evidence pointing to autocrine/paracrine signaling systems as modulators of cardiac dysfunction has increased interest in the emerging role of endothelins as mediators of cardiac function following particulate matter exposure. Endothelin-1, a well-described small peptide expressed in the pulmonary and cardiovascular systems, is best known for its ability to constrict blood vessels, although it can also induce extravascular effects. Research on the role of endothelins in the context of air pollution has largely focused on vascular effects, with limited investigation of responses resulting from the direct effects of endothelins on cardiac tissue. This represents a significant knowledge gap in air pollution health effects research, given the abundance of endothelin receptors found on cardiac tissue and the ability of endothelin-1 to modulate cardiac contractility, heart rate, and rhythm. The plausibility of endothelin-1 as a mediator of particulate matter-induced cardiac dysfunction is further supported by the therapeutic utility of certain endothelin receptor antagonists. The present review examines the possibility that endothelin-1 release caused by exposure to PM directly modulates extravascular effects on the heart, deleteriously altering cardiac function.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390286 | PMC |
http://dx.doi.org/10.1016/j.pharmthera.2016.05.006 | DOI Listing |
J Obes Metab Syndr
September 2025
Integrated Perioperative Geriatric Excellent Research Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Background: Morbid obesity is a well-established risk factor for cardiovascular disease. Diastolic dysfunction, particularly in non-cardiac surgeries, has been associated with increased incidence of adverse cardiovascular events. This study aimed to evaluate the prevalence of diastolic dysfunction in morbidly obese patients undergoing bariatric surgery and to identify associated clinical risk factors using transesophageal echocardiography (TEE).
View Article and Find Full Text PDFComput Methods Programs Biomed
August 2025
CardioVascular Systems Imaging and Artificial Intelligence Lab, National Heart Centre Singapore, Singapore; Duke-NUS Medical School, Singapore; Department of Biomedical Engineering, National University of Singapore, Singapore. Electronic address:
Background And Objective: To develop an end-to-end artificial intelligence solution-video-based Multi-Point Tracking Network (MPTN), for detecting and tracking atrioventricular junction (AVJ) points from cardiovascular magnetic resonance and deriving AVJ motion parameters.
Methods: The MPTN model consists of two modules: AVJ point detection and AVJ motion tracking. The detection module utilizes convolutional-based feature extraction and elastic regression to detect all candidate AVJ points.
Int J Cardiol
September 2025
Federico II University, Naples, Italy; Federico II University Hospital, Naples, Italy. Electronic address:
Background: Peripartum cardiomyopathy (PPCM) is a rare, life-threatening form of heart failure occurring in late pregnancy or postpartum, with variable clinical course and outcomes. We report preliminary clinical and echocardiographic findings from a national Italian registry of PPCM patients METHODS: The study was approved by the institutional Ethics Committee and registered at ClinicalTrials.gov (NCT05878041).
View Article and Find Full Text PDFJ Heart Lung Transplant
September 2025
Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:
Am J Med Sci
September 2025
Division of Gastroenterology and Hepatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Background: Metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis is now the second leading indication for liver transplantation (LT) worldwide and is associated with increased risk of cardiovascular events before and after LT. Cirrhotics who undergo left heart catheterization (LHC) with coronary artery stenting for LT evaluation require dual-antiplatelet therapy (DAPT). Data regarding the safety, risk of gastrointestinal (GI) bleeding, and mortality risk of cirrhotics receiving DAPT is limited.
View Article and Find Full Text PDF